ORGANOGENESIS HOLDINGS INC
Organogenesis Holdings Inc is a biotechnology company focused on developing regenerative medicine products and technologies for treating and healing wounds.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Organogenesis stock with a target price of $5.5, indicating significant growth potential.
Financial Health
Organogenesis is generating reasonable revenue and cash flow, but profitability is quite low.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring ORGO
3D-Bioprinted Tissues
These cutting-edge companies are building the future of medicine by printing living human tissues layer by layer. Selected by expert analysts, this collection represents one of healthcare's most promising frontiers with potential to revolutionize transplantation and drug development.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Commercial traction
Revenue growth and hospital adoption indicate commercial traction; monitor sales trends and distribution metrics, though performance can vary.
Innovation pipeline
New product development and clinical data can drive long-term value, but trials and approvals carry uncertainty and timing risk.
Reimbursement landscape
Reimbursement and procurement policies shape uptake in healthcare settings; policy shifts can materially affect revenues.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Eli Lilly and Company
Eli Lilly & Co is a global pharmaceutical company that develops, manufactures and markets human prescription drugs.
Johnson & Johnson
Johnson & Johnson is a multinational conglomerate pharmaceutical, medical devices, and consumer packaged goods company.
AbbVie Inc.
Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.
